Hypernil is a prescription antihypertensive medication formulated with the active ingredient amlodipine besylate, designed to provide consistent, 24-hour control of elevated blood pressure. As a calcium channel blocker, it effectively relaxes and widens blood vessels, reducing cardiac workload and improving systemic circulation. Clinically proven to lower both systolic and diastolic readings, Hypernil supports long-term management of hypertension with a well-established efficacy and safety profile. It is suitable for monotherapy or combination treatment, aligning with current clinical guidelines for cardiovascular risk reduction.

Features

• Contains amlodipine besylate 5 mg or 10 mg per tablet
• Once-daily dosing ensures steady therapeutic plasma levels
• Bioavailability of approximately 64–90% with minimal food interaction
• Onset of action within 6–12 hours; peak effect at 24 hours
• Extended half-life of 30–50 hours supports missed-dose forgiveness
• Manufactured under cGMP standards with consistent tablet scoring for accurate splitting

Benefits

• Significantly reduces systolic and diastolic blood pressure within two weeks
• Lowers risk of myocardial infarction, stroke, and other hypertension-related complications
• Improves exercise tolerance and reduces angina episodes in patients with coronary artery disease
• Minimizes vascular resistance without compromising heart rate in most patients
• Supports adherence through simple, once-daily regimen
• Compatible with many common antihypertensive combinations for tailored treatment plans

Common use

Hypernil is primarily indicated for the management of hypertension in adults. It may be used as initial monotherapy or as part of a combination regimen with other antihypertensive agents such as ACE inhibitors, beta-blockers, or diuretics. It is also prescribed for chronic stable angina and vasospastic (Prinzmetal’s) angina. Off-label uses may include Raynaud’s phenomenon and certain cases of pediatric hypertension under specialist supervision.

Dosage and direction

The recommended initial dose for most adults is 5 mg taken orally once daily. Dosage may be increased to a maximum of 10 mg daily based on individual blood pressure response and tolerability. Small or frail patients, those with hepatic impairment, or elderly individuals may be started on 2.5 mg daily. Tablets should be swallowed whole with water, with or without food, preferably at the same time each day. Dosage adjustments should be made at 7- to 14-day intervals. Do not crush or chew tablets.

Precautions

• Regular monitoring of blood pressure and heart rate is advised, especially during dosage titration.
• Use with caution in patients with severe aortic stenosis, heart failure, or hepatic impairment.
• May cause peripheral edema; dose reduction or combination therapy may mitigate this effect.
• Abrupt withdrawal may lead to rebound hypertension or angina; taper under medical supervision if discontinuation is necessary.
• Not recommended during pregnancy unless potential benefit justifies potential risk to the fetus.

Contraindications

Hypernil is contraindicated in patients with known hypersensitivity to amlodipine or other dihydropyridine derivatives. It should not be used in individuals with severe hypotension (systolic BP < 90 mmHg) or cardiogenic shock. Concomitant use with strong CYP3A4 inducers or inhibitors may require caution or alternative therapy.

Possible side effects

Common side effects (≥1%) include peripheral edema, headache, dizziness, flushing, fatigue, and palpitations. Less frequently, patients may experience nausea, abdominal pain, somnolence, or gingival hyperplasia. Rare but serious adverse reactions include hypotension, syncope, arrhythmias, and marked edema. Allergic reactions such as rash, pruritus, or angioedema are uncommon but possible.

Drug interaction

Hypernil may interact with:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) — may increase amlodipine levels.
• Simvastatin — concurrent use may increase simvastatin exposure.
• Other antihypertensives or vasodilators — may potentiate hypotensive effects.
• Sildenafil and other PDE5 inhibitors — may enhance blood pressure-lowering effect.
• Cyclosporine — may increase cyclosporine concentrations.

Missed dose

If a dose is missed, take it as soon as remembered on the same day. If it is nearly time for the next dose, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed one.

Overdose

Overdose may lead to pronounced hypotension and reflex tachycardia. In cases of severe overdose, vasodilation may result in shock and fatal outcomes. Management includes cardiovascular monitoring, elevation of extremities, and administration of vasoconstrictors such as dopamine or norepinephrine under clinical supervision. Gastric lavage or activated charcoal may be considered if ingestion was recent.

Storage

Store at room temperature (15–30°C or 59–86°F) in a dry place, protected from light and moisture. Keep in the original container with the lid tightly closed. Do not use after the expiration date printed on the packaging. Keep out of reach of children and pets.

Disclaimer

Hypernil is a prescription medication and should be used only under the supervision of a qualified healthcare provider. This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult your physician before starting, changing, or discontinuing any medication.

Reviews

Clinical studies and post-marketing surveillance consistently report high patient satisfaction with Hypernil, noting its effectiveness in achieving blood pressure targets with a manageable side effect profile. Many users appreciate the once-daily convenience and stability of control over 24 hours. Healthcare providers often recommend it for its reliability and compatibility with other cardiovascular agents.